PMID- 1702633
OWN - NLM
STAT- MEDLINE
DCOM- 19910208
LR  - 20190623
IS  - 0006-2952 (Print)
IS  - 0006-2952 (Linking)
VI  - 41
IP  - 1
DP  - 1991 Jan 1
TI  - Effect of 3,4-methylenedioxymethamphetamine on [3H]paroxetine binding in the 
      frontal cortex and blood platelets of rats.
PG  - 79-84
AB  - The effects of single or repeated administration of the racemic mixture of 
      3,4-methylenedioxymethamphetamine (MDMA; 20 mg/kg, s.c.) on the number (Bmax) of 
      serotonin (5-HT) uptake sites as determined by [3H]paroxetine binding and the 
      concentration of 5-HT and its major metabolite, 5-hydroxyindoleacetic acid 
      (5-HIAA), were measured in the frontal cortex and blood platelets of rats 1 and 7 
      days following its administration. A single injection of MDMA significantly (P 
      less than 0.05) decreased the number of [3H]paroxetine binding sites as well as 
      the concentrations of 5-HT and 5-HIAA in the frontal cortex but not in platelets 
      7 days following administration. Repeated injections of MDMA (twice daily for 4 
      days) significantly (P less than 0.05) decreased the number of 5-HT uptake sites 
      and the concentration of 5-HT and 5-HIAA in the frontal cortex but not in 
      platelets 7 days following administration. Pretreatment with the 5-HT2/5-HT1C 
      antagonist, ketanserin, inhibited the MDMA-induced decrease in 5-HT and 5-HIAA 
      concentrations and the number of [3H]paroxetine binding sites in the frontal 
      cortex 7 days following a single administration. These data are suggestive that 
      blood platelets are less sensitive than brain tissue to the 5-HT-depleting 
      effects of MDMA. The ability of ketanserin pretreatment to block MDMA-induced 
      decreases in [3H]paroxetine binding sites in the frontal cortex is suggestive 
      that 5-HT2/5-HT1C receptors may be involved in the neurotoxic effects of MDMA.
FAU - Nash, J F
AU  - Nash JF
AD  - Department of Psychiatry, School of Medicine, Case Western Reserve University, 
      Cleveland, OH 44106.
FAU - Arora, R C
AU  - Arora RC
FAU - Schreiber, M A
AU  - Schreiber MA
FAU - Meltzer, H Y
AU  - Meltzer HY
LA  - eng
GR  - M01RR00080/RR/NCRR NIH HHS/United States
GR  - MH41594/MH/NIMH NIH HHS/United States
GR  - MH41684/MH/NIMH NIH HHS/United States
GR  - etc.
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Biochem Pharmacol
JT  - Biochemical pharmacology
JID - 0101032
RN  - 0 (Piperidines)
RN  - 0 (Serotonin Antagonists)
RN  - 10028-17-8 (Tritium)
RN  - 333DO1RDJY (Serotonin)
RN  - 41VRH5220H (Paroxetine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - 97F9DE4CT4 (Ketanserin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/administration & dosage/*analogs & 
      derivatives/antagonists & inhibitors/pharmacology
MH  - Animals
MH  - Blood Platelets/*drug effects/metabolism
MH  - Frontal Lobe/*drug effects/metabolism
MH  - Hydroxyindoleacetic Acid/metabolism
MH  - Ketanserin/administration & dosage
MH  - Kinetics
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Paroxetine
MH  - Piperidines/*metabolism
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Serotonin/metabolism
MH  - Serotonin Antagonists/*metabolism
MH  - Time Factors
MH  - Tritium
EDAT- 1991/01/01 00:00
MHDA- 1991/01/01 00:01
CRDT- 1991/01/01 00:00
PHST- 1991/01/01 00:00 [pubmed]
PHST- 1991/01/01 00:01 [medline]
PHST- 1991/01/01 00:00 [entrez]
AID - 0006-2952(91)90013-U [pii]
AID - 10.1016/0006-2952(91)90013-u [doi]
PST - ppublish
SO  - Biochem Pharmacol. 1991 Jan 1;41(1):79-84. doi: 10.1016/0006-2952(91)90013-u.